Safety and Effectiveness of Levosimendan in Patients with Predominant Right Heart Failure

@article{Poelzl2008SafetyAE,
  title={Safety and Effectiveness of Levosimendan in Patients with Predominant Right Heart Failure},
  author={Gerhard Poelzl and Ralph H. Zwick and Willhelm Grander and B. Metzler and Patrycja Jonetzko and Mathias Frick and Hanno Ulmer and Otmar Pachinger and Franz Xaver Roithinger},
  journal={Herz Kardiovaskul{\"a}re Erkrankungen},
  year={2008},
  volume={33},
  pages={368-373}
}
Levosimendan is a new calcium sensitizer that enhances the contractile force of the myocardium and exhibits additional vasodilating properties. The present study describes the hemodynamic effects of levosimendan in patients with acute predominant right heart failure in need of inotropic therapy. 18 patients (15 male, age 60 ± 17 years) with acute heart failure, predominant right ventricular dysfunction, left ventricular ejection fraction (LVEF) ≤ 30%, cardiac index (CI) ≤ 2.5 l/min/m2, right… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 17 references

Randomized study on safety and effectiveness of levosimendan in patients with left ventricular heart failure after an acute myocardial infarction (the RUSSLAN study)

  • VS Moiseyev, P Poder, N Andrejevs
  • Eur Heart J 2002;23:1422–32
  • 2002
1 Excerpt

Similar Papers

Loading similar papers…